Signal Transduction Program
-
New melanoma drug nearly doubles survival in majority of patients
Investigators from Vanderbilt-Ingram Cancer Center and 12 other centers in the United States and Australia have found that a new drug for patients with metastatic melanoma nearly doubled median overall survival. Read MoreFeb 23, 2012